The regenerative medicine company says the laws which passed through Parliament in November 2013 have now come into effect. 

 

The new laws reform the pharmaceutical and medical regulations related to regenerative medicine and provide a rapid approval process.  

 

CEO John Martin says the laws provide Regeneus with a unique opportunity to fast track the clinical trial and seek approval of its new allogeneic off-the-shelf cell therapy product, PRG, to treat human osteoarthritis in the Japanese market. 

 

Regeneus reported a net loss of $7.5 million in the 2014 financial year.